PriceTargets.com logo

Shattuck Labs - STTK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.67
  • Forecasted Upside: 549.19%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$1.34 As of 10/30/2024 03:38 PM ET
▼ -0.005 (-0.37%)

This chart shows the closing price for STTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shattuck Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STTK

Analyst Price Target is $8.67
▲ +549.19% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Shattuck Labs in the last 3 months. The average price target is $8.67, with a high forecast of $16.00 and a low forecast of $2.00. The average price target represents a 549.19% upside from the last price of $1.34.

This chart shows the closing price for STTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Shattuck Labs. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/2/2024Evercore ISIUpgradeStrong-Buy
10/2/2024CitigroupDowngradeBuy ➝ Neutral$8.00 ➝ $2.00
10/2/2024Needham & Company LLCDowngradeBuy ➝ Hold$8.00
10/1/2024HC WainwrightDowngradeBuy ➝ Neutral
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
8/15/2024CitigroupLower TargetBuy ➝ Buy$9.00 ➝ $8.00
8/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
8/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
6/20/2024HC WainwrightLower TargetBuy ➝ Buy$28.00 ➝ $16.00
6/17/2024CitigroupLower TargetBuy ➝ Buy$10.00 ➝ $9.00
6/17/2024BTIG ResearchDowngradeBuy ➝ Neutral
6/14/2024Needham & Company LLCLower TargetBuy ➝ Buy$12.00 ➝ $8.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
5/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
5/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
3/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
2/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
2/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
8/11/2023Needham & Company LLCLower TargetBuy ➝ Buy$14.00 ➝ $12.00
4/20/2023Needham & Company LLCReiterated RatingBuy$14.00
4/20/2023HC WainwrightReiterated RatingBuy$28.00
4/3/2023HC WainwrightReiterated RatingBuy$28.00
3/9/2023CitigroupLower Target$13.00 ➝ $9.00
2/24/2023HC WainwrightReiterated RatingBuy$28.00
2/24/2023Needham & Company LLCLower TargetBuy$21.00 ➝ $14.00
2/13/2023HC WainwrightReiterated RatingBuy$28.00
8/31/2022BTIG ResearchInitiated CoverageBuy$12.00
8/12/2022Needham & Company LLCLower TargetBuy$31.00 ➝ $21.00
6/3/2022HC WainwrightReiterated RatingBuy$28.00
6/1/2022CitigroupInitiated CoverageBuy$13.00
5/2/2022HC WainwrightInitiated CoverageBuy$28.00
3/16/2022Needham & Company LLCLower TargetBuy$46.00 ➝ $31.00
4/14/2021Berenberg BankInitiated CoverageBuy$47.00
1/20/2021CitigroupBoost Target$36.00 ➝ $75.00
1/11/2021Evercore ISIInitiated CoverageOutperform
11/3/2020Smith Barney CitigroupInitiated CoverageBuy$36.00
11/3/2020CowenInitiated CoverageOutperform
11/3/2020Needham & Company LLCInitiated CoverageBuy$34.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 4 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 4 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Shattuck Labs logo
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.34
Low: $1.32
High: $1.38

50 Day Range

MA: $2.67
Low: $1.13
High: $3.87

52 Week Range

Now: $1.34
Low: $1.07
High: $11.76

Volume

95,646 shs

Average Volume

456,606 shs

Market Capitalization

$63.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Shattuck Labs?

The following sell-side analysts have issued stock ratings on Shattuck Labs in the last year: BTIG Research, Citigroup Inc., Evercore ISI, HC Wainwright, and Needham & Company LLC.
View the latest analyst ratings for STTK.

What is the current price target for Shattuck Labs?

3 Wall Street analysts have set twelve-month price targets for Shattuck Labs in the last year. Their average twelve-month price target is $8.67, suggesting a possible upside of 549.2%. HC Wainwright has the highest price target set, predicting STTK will reach $16.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $2.00 for Shattuck Labs in the next year.
View the latest price targets for STTK.

What is the current consensus analyst rating for Shattuck Labs?

Shattuck Labs currently has 4 hold ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in STTK, but not buy more shares or sell existing shares.
View the latest ratings for STTK.

What other companies compete with Shattuck Labs?

Other companies that are similar to Shattuck Labs include Editas Medicine, Acrivon Therapeutics, TScan Therapeutics, Amarin and Cadrenal Therapeutics. Learn More about companies similar to Shattuck Labs.

How do I contact Shattuck Labs' investor relations team?

The company's listed phone number is 512-900-4690 and its investor relations email address is [email protected]. The official website for Shattuck Labs is www.shattucklabs.com. Learn More about contacing Shattuck Labs investor relations.